Dyadic International DYAI
NASDAQ DYAI
$0.49 -0.02 (-3.92%)
As of: Sep 10, 2026 · 3:51 PM EDT

Dyadic International (DYAI) Cost of Revenue (2018 - 2025)

Dyadic International's (DYAI) quarterly Cost of Revenue came in at $297658.0 in Q1 2025, up 106.77% year-over-year from $143955.0 in Q1 2024, and down 15.63% quarter-over-quarter from $352819.0 in Q4 2024.

Analysis

Dyadic International (DYAI) Cost of Revenue (2018 - 2025) Analysis & Trends

Dyadic International has disclosed Cost of Revenue across 8 years of filings, most recently posting $297658.0 for Q1 2025.

  • In Q1 2025, Cost of Revenue rose 106.77% year-over-year to $297658.0; the TTM figure through Mar 2025 stood at $1.3 million (down 3.2% YoY), while the FY2024 annual figure was $1.2 million, down 39.54% from the prior year.
  • Cost of Revenue came in at $297658.0 for Q1 2025 at Dyadic International, down from $352819.0 in the prior quarter.
  • In the past five years, Cost of Revenue ranged from a high of $390.8 million in Q1 2021 to a low of $105869.0 in Q3 2023.
  • Average Cost of Revenue over 5 years is $23.4 million, with a median of $395894.0 recorded in 2024.
  • Year-over-year, Cost of Revenue jumped 140369.91% in 2021 and sank 99.9% in 2022.
  • Over 5 years, Cost of Revenue stood at $331628.0 in 2021, then surged by 112.43% to $704491.0 in 2022, then slumped by 50.3% to $350118.0 in 2023, then advanced by 0.77% to $352819.0 in 2024, then retreated by 15.63% to $297658.0 in 2025.
  • Per Business Quant data, the three most recent Cost of Revenue figures were $297658.0 in Q1 2025, $352819.0 in Q4 2024, and $395894.0 in Q3 2024.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cost of Rev (Qtr)
1 Amgen 206.58 Bn 192.59 Bn 7.24 Bn 2.81 Bn
2 Gilead Sciences 180.17 Bn 176.99 Bn 6.22 Bn 1.58 Bn
3 Vertex Pharmaceuticals 130.59 Bn 122.74 Bn 2.84 Bn 489.20 Mn
4 Regeneron Pharmaceuticals 81.61 Bn 73.61 Bn 3.93 Bn 360.70 Mn
5 Argenx Se 60.24 Bn 55.05 Bn 1.37 Bn 145.00 Mn
6 Moderna 54.29 Bn 49.15 Bn 52.00 Mn 93.00 Mn
7 Alnylam Pharmaceuticals 32.96 Bn 29.65 Bn 992.69 Mn 298.26 Mn
8 Biogen 31.94 Bn 30.66 Bn 1.96 Bn 776.90 Mn
9 Roivant Sciences 29.38 Bn 29.38 Bn 1.16 Mn 284,000.00
10 Dyadic International 17.78 Mn 9.82 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2025 297,658.00
Dec 31, 2024 352,819.00
Sep 30, 2024 395,894.00
Jun 30, 2024 301,956.00
Mar 31, 2024 143,955.00
Dec 31, 2023 350,118.00
Sep 30, 2023 105,869.00
Jun 30, 2023 792,944.00
Mar 31, 2023 726,918.00
Dec 31, 2022 704,491.00
Sep 30, 2022 602,847.00
Jun 30, 2022 411,109.00
Mar 31, 2022 404,746.00
Dec 31, 2021 331,628.00
Sep 30, 2021 392,544.00
Jun 30, 2021 829,504.00
Mar 31, 2021 390.76 Mn
Dec 31, 2020 255,580.00
Sep 30, 2020 266,929.00
Jun 30, 2020 624,240.00